Related Experiment Video
Updated: Jun 6, 2025

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
Does the Diffusion Profile Differ Between Botulinum Toxin Type a Formulations? Implications for the Management of
Alessandro Picelli1,2,3, Stefano Tamburin1,2, Rita Di Censo1,2
1Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Botulinum toxin type A is a key treatment for post-stroke spasticity. Its diffusion is controlled by dose, dilution, and volume, not formulation, impacting therapeutic benefits.
Area of Science:
- Neurology
- Pharmacology
- Biochemistry
Background:
- Botulinum toxin type A is a primary treatment for post-stroke spasticity.
- Concerns regarding toxin diffusion and spread influence treatment decisions.
- Understanding diffusion is crucial for optimizing therapeutic outcomes.
Purpose of the Study:
- To clarify the factors influencing botulinum toxin type A diffusion and spread in post-stroke spasticity.
- To differentiate between formulation-dependent and injection-dependent factors affecting diffusion.
- To inform clinical practice regarding the control of toxin spread for therapeutic benefit or avoidance.
Main Methods:
- Review of current evidence on botulinum toxin type A formulations and diffusion.
- Analysis of factors influencing toxin spread, including dose, dilution, and injection volume.
- Consideration of secondary factors like needle gauge and injection speed.
Main Results:
- Different botulinum toxin type A formulations do not exhibit varying diffusion profiles.
- Key determinants of diffusion and spread are dose, dilution, and injection volume.
- Injection-related factors like needle gauge and speed play a secondary role.
Conclusions:
- Botulinum toxin type A diffusion can be managed by adjusting dose, dilution, and volume.
- Controlled diffusion can enhance therapeutic effects by reaching more nerve terminals.
- Careful evaluation of these factors is essential in spasticity clinics for personalized treatment.
More Related Videos
08:40Isokinetic Robotic Device to Improve Test-Retest and Inter-Rater Reliability for Stretch Reflex Measurements in Stroke Patients with Spasticity
Published on: June 12, 2019
14:10A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
Published on: November 14, 2014
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses